ClinicalTrials.gg
CompletedNCT06059729Al-LisaanUpdated Apr 3, 2024

Effects of Al-Lisaan Urdu Digital Software for Self-Assessment and Treatment of Adult Stutters

An interventional study of Al-Lisaan in Stuttering, Adult, sponsored by Riphah International University. Completed at 2 sites in Pakistan. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The study plans to find the efficacy of a digital application/software, Al-lisan that adult stutters can be used for assessment and management of their stuttering. The Software has been developed with the help of a software engineer. After the current trends employed by Speech language pathologists explored through qualitative study design, the manual which is under development process through a focused group in which assessment and treatment options of the software were finalized. The next step will include the reliability and validity of the software for assessment and management of adult stutters followed by finding the efficacy of the software. As this Application will be in Urdu language it will assist less literate and those living in peripheries to assess or provide self-treatment options to the persons who stutter. It will allow adults for self-assessment and treatment options in Urdu language.

Read the detailed description

The term stuttering refers to the dis-fluent pattern of speech. In adult stuttering it's a learned pattern of dis-fluent production that may become the part of their speech permanently. It affects 1% of the worldwide population. There are many therapeutic techniques to treat the stuttering in adults. Self-help therapy is common to use. Besides the personalized treatment of self-help therapy by adult stutters, there are many digital applications available and used by many adult stutters worldwide. Few are StammerApp, Stamurai and SMAAT. The objective of the study is to develop a digital application/software that adult stutters can be used for assessment and management of their stuttering. This study being a part of PhD project, started in March 2020 and until now, the current trends employed by Speech language pathologists have been explored through qualitative study design. The manual was developed through a focused group in which assessment and treatment options of the software were finalized. The Software has been developed with the help of a software engineer. The objective of this study is to find the effects of Al-lisan Urdu Digital Software for Self-Assessment and Treatment of Adult Stutters. For this step we are applying for the grant. As this Application will be in Urdu language it will assist less literate and those living in peripheries to assess or provide self-treatment options to the persons who stutter. It will allow adults for self-assessment and treatment options in Urdu language.

02

Conditions studied

  • Stuttering, Adult

Browse trials for

03

In context

Stuttering

74 studies on the registry are indexed under Stuttering; 23 are open to participants now.

This study's enrollment of 52 is above the median of 44 across 57 interventional studies indexed under Stuttering.

Browse Stuttering studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,193 studies on the registry; 650 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria will be Stutters who are above the age of 19 and who have not taken regular therapy from last one year

Exclusion criteria

Exclusion Criteria:

Adults with neurogenic stuttering or any other organic cause will be excluded

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Experimental group

    Al-Lisaan digital application will be given to participants for self assessment and management

    Device: Al-Lisaan

  • Other
    Controlled group

    Home plan will be given

    Device: Al-Lisaan

Interventions

  • DeviceAl-Lisaan

    Al-Lisaan is a digital application for the self assessment and management of adult stutters.

06

What researchers measure

Primary outcomes

  1. Stutter Severity Index

    Stutter's severity will be measured Pre and Post experimental study.

    Time frame: six weeks

Secondary outcomes

  1. Stuttering Severity Index

    Stutter's severity will be measured Pre and Post experimental study.

    Time frame: six weeks

07

Study locations

2 sites
  • Hafsa Noreen
    Lahore, Punjab, Pakistan
  • Rex Medical Center
    Lahore, Punjab, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2023, 2 months.

Of 37 interventional studies with no phase under Stuttering, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Sep 29, 2023
StartActual
Sep 11, 2023
Primary completionActual
Dec 1, 2023
CompletionActual
Jan 1, 2024
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059729
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Sep 11, 2023
Primary completion
Dec 1, 2023
Completion
Jan 1, 2024
Last update
Apr 3, 2024

Study contacts

hafsa Noreen, PhD*
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion